EVOK Evoke Pharma Inc

USD 0.47 -0.01 -2.151211
Icon

Evoke Pharma Inc (EVOK) Stock Analysis and Price Targets

COMMON STOCK | Drug Manufacturers - Specialty & Generic | NSD
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.4685

-0.01 (-2.15)%

USD 5.00M

1.94K

N/A

N/A

Icon

EVOK

Evoke Pharma Inc (USD)
COMMON STOCK | NSD
USD 0.47
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 5.00M

N/A

USD 0.47

Evoke Pharma Inc (EVOK) Stock Forecast

N/A

Based on the Evoke Pharma Inc stock forecast from 0 analysts, the average analyst target price for Evoke Pharma Inc is not available over the next 12 months. Evoke Pharma Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Evoke Pharma Inc is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, Evoke Pharma Inc’s stock price was USD 0.4685. Evoke Pharma Inc’s stock price has changed by -8.14% over the past week, -23.07% over the past month and -77.69% over the last year.

No recent analyst target price found for Evoke Pharma Inc
No recent average analyst rating found for Evoke Pharma Inc

Company Overview Evoke Pharma Inc

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and ...Read More

https://evokepharma.com

420 Stevens Avenue, Solana Beach, CA, United States, 92075

4

December

USD

USA

Adjusted Closing Price for Evoke Pharma Inc (EVOK)

Loading...

Unadjusted Closing Price for Evoke Pharma Inc (EVOK)

Loading...

Share Trading Volume for Evoke Pharma Inc Shares

Loading...

Compare Performance of Evoke Pharma Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for EVOK

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Evoke Pharma Inc (Sector: Drug Manufacturers - Specialty & Generic )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VTRS
Viatris Inc +0.13 (+1.17%) USD14.11B 237.70 8.88

ETFs Containing EVOK

Symbol Name EVOK's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Evoke Pharma Inc (EVOK) Stock

Stock Target Advisor's fundamental analysis for Evoke Pharma Inc's stock is Bearish.

Unfortunately we do not have enough data on EVOK's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on EVOK's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on EVOK's stock to indicate if its overvalued.

The last closing price of EVOK's stock was USD 0.47.

The most recent market capitalization for EVOK is USD 5.00M.

Unfortunately we do not have enough analyst data on EVOK's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Evoke Pharma Inc's stock.

As per our most recent records Evoke Pharma Inc has 4 Employees.

Evoke Pharma Inc's registered address is 420 Stevens Avenue, Solana Beach, CA, United States, 92075. You can get more information about it from Evoke Pharma Inc's website at https://evokepharma.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...